Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
about
Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2A full-length infectious cDNA clone of Zika virus from the 2015 epidemic in Brazil as a genetic platform for studies of virus-host interactions and vaccine developmentFunctions of the 3' and 5' genome RNA regions of members of the genus FlavivirusMouse models to study dengue virus immunology and pathogenesisRecombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypesVaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeysSubstitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoesIssues related to recent dengue vaccine development.The 5' and 3' Untranslated Regions of the Flaviviral Genome.Current progress in dengue vaccinesGenetically modified organisms and visceral leishmaniasisBioinformatics in new generation flavivirus vaccines.RNA virus reverse genetics and vaccine design.Genetic and phenotypic characterization of sylvatic dengue virus type 4 strainsDevelopment and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization.Dengue vaccines: recent developments, ongoing challenges and current candidates.Successful propagation of flavivirus infectious cDNAs by a novel method to reduce the cryptic bacterial promoter activity of virus genomes.Chimeric tick-borne encephalitis/dengue virus is attenuated in Ixodes scapularis ticks and Aedes aegypti mosquitoes.Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccineDistinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2Full-length infectious clone of a low passage dengue virus serotype 2 from BrazilTargeted mutagenesis as a rational approach to dengue virus vaccine development.Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor.An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.Construction and characterisation of a complete reverse genetics system of dengue virus type 3.Characterization of cis-acting RNA elements of Zika virus by using a self-splicing ribozyme-dependent infectious clone.
P2860
Q24805308-8FC32D46-F853-45A2-BAB3-5E81DEC8F379Q26681254-43995E92-4A7A-4DDE-B168-0EB4F584CAD7Q26700111-CFB41B11-1DF3-4353-BF31-389249400E80Q27010151-4D323616-9607-471F-B920-D9E4C50B0AF7Q27469474-5F963E7E-33C9-4DAF-B1F9-A72AA76BEF0BQ27478104-AFF49C85-1B74-44C0-87E2-9D3CADEE9353Q27478162-27EAD5C3-5F72-413A-9D28-372421E45D86Q27485404-076E4E6D-9FF1-47AF-AE8A-F01DC34D7D26Q27487013-92DE5407-6C1D-4831-BBA0-C7EE9547B62BQ27487448-1BEE3D90-C48A-4F93-B644-063A1087F438Q30395396-2A1897BD-ED85-4FA3-943C-8A536661C07DQ32183359-4197CE01-589A-4638-886A-03B9ED69444FQ33408300-A6611B59-D79A-4A8D-B0BD-4F159929DC12Q33647026-F650B94B-7A99-45D3-92A0-6FAE0EE5085BQ33839001-592F1FF7-D545-41AC-AD78-054B122CF295Q33963398-8BA74F8E-DA30-4B26-913E-5A19F0051DB4Q34104330-B84F73EB-8B82-4023-BA64-AD4042E6312AQ34184711-5107EDD3-366E-4E54-9214-25E4CBCA7F5FQ34367194-625A2DB8-3659-498E-BE37-F8EC50DCCA46Q34742978-53CBDDB0-85D9-423D-8EBD-A3F86118D8F9Q35046285-71AF31F2-0D90-4ED5-A52C-315DAC255B9BQ35206695-D2BD8AC6-ABB6-482D-8E75-3E699F4177CCQ35624552-D64A355A-DB7D-4DFD-83AE-0A63F7421AD9Q36059707-F719E96E-3C00-4EE2-8604-4C9E009D9046Q36118259-E7695082-1B5D-4ED6-9333-618C75E91437Q36523226-9796E0E7-29CD-4339-AC8E-A33D7C8126ACQ36667964-5E3BF1B3-50E9-416A-9CDB-BF3DA6131459Q37734118-DEC44357-70CC-48E8-BB73-8B7B13D26B13Q38156722-2EBB4873-EEE4-439E-A1A6-E3D0FCDC1934
P2860
Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
@ast
Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
@en
type
label
Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
@ast
Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
@en
prefLabel
Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
@ast
Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
@en
P2093
P1476
Genetically modified, live attenuated dengue virus type 3 vaccine candidates.
@en
P2093
Brian R Murphy
Cai-Yen Firestone
Christopher T Hanson
Joseph E Blaney
Kathryn A Hanley
P304
P407
P577
2004-12-01T00:00:00Z